Nuclear factor erythroid 2 - related factor 2 signaling in Parkinson disease: A promising multi therapeutic target against oxidative stress, neuroinflammation and cell death

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 8, 2012, Pages 1015-1029

  Kumar, Hemant ^a   Koppula, Sushruta ^a   Kim, In Su ^a   More, Sandeep Vasant ^a   Kim, Byung Wook ^a   Choi, Dong Kug ^a  

^a Konkuk University   (South Korea)

Author keywords

Antioxidant inflammation modulators; Antioxidant response elements; Apoptosis; Neuroinflammation; Nuclear factor erythroid 2 related factor 2; Oxidative stress; Parkinson's disease

Indexed keywords

APOMORPHINE; ARTESUNATE; BARDOXOLONE METHYL; BROMOCRIPTINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; ERIODICTYOL; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 9; GINSENOSIDE RB 1; GLUTATHIONE; HEME OXYGENASE 1; KAHWEOL; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LUTEOLIN; METALLOTHIONEIN III; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); ROSIGLITAZONE; SCAVENGER; SELEGILINE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL DEATH; DOWN REGULATION; ELECTROPHILIC STRESS; EXCITOTOXICITY; GENE EXPRESSION REGULATION; HUMAN; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROPROTECTION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; ANTIPARKINSON AGENTS; CARBOXYLIC ESTER HYDROLASES; CELL DEATH; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 84875037694     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311211080012     Document Type: Article

References (176)

1. Brand, M.D.; Affourtit, C.; Esteves, T.C.; Green, K.; Lambert, A.J.; Miwa, S.; Pakay, J.L.; Parker, N. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med., 2004, 37(6), 755-767.
2. Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol., 2003, 552(Pt 2), 335-344.
3. Finkel, T. Oxygen radicals and signaling. Curr. Opin. Cell Biol., 1998, 10(2), 248-253.
4. Finkel, T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol., 2003, 15(2), 247-254.
5. Nguyen, T.; Sherratt, P.J.; Huang, H.C.; Yang, C.S.; Pickett, C.B. Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J. Biol. Chem., 2003, 278(7), 4536-4541.
6. Itoh, K.; Tong, K.I.; Yamamoto, M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med., 2004, 36(10), 1208-1213.
7. Motohashi, H.; Yamamoto, M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med., 2004, 10(11), 549-557.
8. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel, J.D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev., 1999, 13(1), 76-86.
9. Tufekci, K.U.; Civi Bayin, E.; Genc, S.; Genc, K. The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease. Parkinsons Dis., 2011, 2011, 314082.
10. Cuadrado, A.; Moreno-Murciano, P.; Pedraza-Chaverri, J. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin. Ther. Targets., 2009, 13(3), 319-329.
11. Przedborski, S.; Ischiropoulos, H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid. Redox Signal., 2005, 7(5-6), 685-693.
12. Schapira, A.H. Pathogenesis of Parkinson's disease. Baillieres Clin. Neurol., 1997, 6(1), 15-36.
13. Dawson, T.M.; Dawson, V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci., 2002, 5 Suppl, 1058-1061.
14. Dawson, T.M.; Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science, 2003, 302(5646), 819-822.
15. Dunnett, S.B.; Bjorklund, A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature, 1999, 399(6738 Suppl), A32-39.
16. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact., 2006, 160(1), 1-40.
17. Finkel, T. Reactive oxygen species and signal transduction. IUBMB Life, 2001, 52(1-2), 3-6.
18. Alam, Z.I.; Daniel, S.E.; Lees, A.J.; Marsden, D.C.; Jenner, P.; Halliwell, B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem., 1997, 69(3), 1326-1329.
19. Alam, Z.I.; Jenner, A.; Daniel, S.E.; Lees, A.J.; Cairns, N.; Marsden, C.D.; Jenner, P.; Halliwell, B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem., 1997, 69(3), 1196-1203.
20. Dexter, D.; Carter, C.; Agid, F.; Agid, Y.; Lees, A.J.; Jenner, P.; Marsden, C.D. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet, 1986, 2(8507), 639-640.
21. Dexter, D.T.; Carter, C.J.; Wells, F.R.; Javoy-Agid, F.; Agid, Y.; Lees, A.; Jenner, P.; Marsden, C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem., 1989, 52(2), 381-389.
22. Dexter, D.T.; Holley, A.E.; Flitter, W.D.; Slater, T.F.; Wells, F.R.; Daniel, S.E.; Lees, A.J.; Jenner, P.; Marsden, C.D. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord., 1994, 9(1), 92-97.
23. Kushnareva, Y.; Murphy, A.N.; Andreyev, A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem. J., 2002, 368(Pt 2), 545-553.
24. Fasano, M.; Bergamasco, B.; Lopiano, L. Modifications of the iron-neuromelanin system in Parkinson's disease. J. Neurochem., 2006, 96(4), 909-916.
25. Greenamyre, J.T.; Hastings, T.G. Biomedicine. Parkinson's--divergent causes, convergent mechanisms. Science, 2004, 304(5674), 1120-1122.
26. Ischiropoulos, H.; Beckman, J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest., 2003, 111(2), 163-169.
27. Koutsilieri, E.; Scheller, C.; Grunblatt, E.; Nara, K.; Li, J.; Riederer, P. Free radicals in Parkinson's disease. J. Neurol., 2002, 249 Suppl 2, II1-5.
28. Slivka, A.; Cohen, G. Hydroxyl radical attack on dopamine. J. Biol. Chem., 1985, 260(29), 15466-15472.
29. Sulzer, D.; Zecca, L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res., 2000, 1(3), 181-195.
30. Scherman, D.; Desnos, C.; Darchen, F.; Pollak, P.; Javoy-Agid, F.; Agid, Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol., 1989, 26(4), 551-557.
31. Chen, L.; Ding, Y.; Cagniard, B.; Van Laar, A.D.; Mortimer, A.; Chi, W.; Hastings, T.G.; Kang, U.J.; Zhuang, X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci., 2008, 28(2), 425-433.
32. Kuhn, D.M.; Arthur, R.E., Jr.; Thomas, D.M.; Elferink, L.A. Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem., 1999, 73(3), 1309-1317.
33. Whitehead, R.E.; Ferrer, J.V.; Javitch, J.A.; Justice, J.B. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J. Neurochem., 2001, 76(4), 1242-1251.
34. LaVoie, M.J.; Ostaszewski, B.L.; Weihofen, A.; Schlossmacher, M.G.; Selkoe, D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med., 2005, 11(11), 1214-1221.
35. Tessari, I.; Bisaglia, M.; Valle, F.; Samori, B.; Bergantino, E.; Mammi, S.; Bubacco, L. The reaction of alpha-synuclein with tyrosinase: possible implications for Parkinson disease. J. Biol. Chem., 2008, 283(24), 16808-16817.
36. Spencer, J.P.; Jenner, P.; Daniel, S.E.; Lees, A.J.; Marsden, D.C.; Halliwell, B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem., 1998, 71(5), 2112-2122.
37. Pearce, R.K.; Owen, A.; Daniel, S.; Jenner, P.; Marsden, C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm., 1997, 104(6-7), 661-677.
38. Berg, D.; Youdim, M.B.; Riederer, P. Redox imbalance. Cell Tissue Res., 2004, 318(1), 201-213.
39. Klegeris, A.; McGeer, E.G.; McGeer, P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol., 2007, 20(3), 351-357.
40. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38(8), 1285-1291.
41. Imamura, K.; Hishikawa, N.; Sawada, M.; Nagatsu, T.; Yoshida, M.; Hashizume, Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta. Neuropathol., 2003, 106(6), 518-526.
42. Gerhard, A.; Pavese, N.; Hotton, G.; Turkheimer, F.; Es, M.; Hammers, A.; Eggert, K.; Oertel, W.; Banati, R.B.; Brooks, D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis., 2006, 21(2), 404-412.
43. Choi, D.K.; Pennathur, S.; Perier, C.; Tieu, K.; Teismann, P.; Wu, D.C.; Jackson-Lewis, V.; Vila, M.; Vonsattel, J.P.; Heinecke, J.W.; Przedborski, S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci., 2005, 25(28), 6594-6600.
44. Knott, C.; Stern, G.; Wilkin, G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and-2. Mol. Cell Neurosci., 2000, 16(6), 724-739.
45. van Leyen, K.; Arai, K.; Jin, G.; Kenyon, V.; Gerstner, B.; Rosenberg, P.A.; Holman, T.R.; Lo, E.H. Novel lipoxygenase inhibitors as neuroprotective reagents. J. Neurosci. Res., 2008, 86(4), 904-909.
46. Merad-Boudia, M.; Nicole, A.; Santiard-Baron, D.; Saille, C.; Ceballos-Picot, I. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem. Pharmacol., 1998, 56(5), 645-655.
47. Gavrieli, Y.; Sherman, Y.; Ben-Sasson, S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 1992, 119(3), 493-501.
48. Kingsbury, A.E.; Mardsen, C.D.; Foster, O.J. DNA fragmentation in human substantia nigra: apoptosis or perimortem effect? Mov. Disord., 1998, 13(6), 877-884.
49. Zatloukal, K.; Stumptner, C.; Fuchsbichler, A.; Heid, H.; Schnoelzer, M.; Kenner, L.; Kleinert, R.; Prinz, M.; Aguzzi, A.; Denk, H. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am. J. Pathol., 2002, 160(1), 255-263.
50. Jain, A.; Lamark, T.; Sjottem, E.; Larsen, K.B.; Awuh, J.A.; Overvatn, A.; McMahon, M.; Hayes, J.D.; Johansen, T. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem., 2010, 285(29), 22576-22591.
51. Nguyen, T.; Sherratt, P.J.; Nioi, P.; Yang, C.S.; Pickett, C.B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J. Biol. Chem., 2005, 280(37), 32485-32492.
52. Moi, P.; Chan, K.; Asunis, I.; Cao, A.; Kan, Y.W. Isolation of NFE2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. U S A, 1994, 91(21), 9926-9930.
53. McMahon, M.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem., 2003, 278(24), 21592-21600.
54. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; O'Connor, T.; Yamamoto, M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells, 2003, 8(4), 379-391.
55. Zhang, D.D.; Hannink, M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell Biol., 2003, 23(22), 8137-8151.
56. Kensler, T.W.; Wakabayashi, N.; Biswal, S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 89-116.
57. Stewart, D.; Killeen, E.; Naquin, R.; Alam, S.; Alam, J. Degradation of transcription factor Nrf2 via the ubiquitinproteasome pathway and stabilization by cadmium. J. Biol. Chem., 2003, 278(4), 2396-2402.
58. McMahon, M.; Thomas, N.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J. Biol. Chem., 2004, 279(30), 31556-31567.
59. Kobayashi, A.; Kang, M.I.; Okawa, H.; Ohtsuji, M.; Zenke, Y.; Chiba, T.; Igarashi, K.; Yamamoto, M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell Biol., 2004, 24(16), 7130-7139.
60. Cullinan, S.B.; Gordan, J.D.; Jin, J.; Harper, J.W.; Diehl, J.A. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol. Cell Biol., 2004, 24(19), 8477-8486.
61. Zhang, D.D.; Lo, S.C.; Cross, J.V.; Templeton, D.J.; Hannink, M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell Biol., 2004, 24(24), 10941-10953.
62. Furukawa, M.; Xiong, Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol. Cell Biol., 2005, 25(1), 162-171.
63. Osburn, W.O.; Wakabayashi, N.; Misra, V.; Nilles, T.; Biswal, S.; Trush, M.A.; Kensler, T.W. Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. Arch. Biochem. Biophys., 2006, 454(1), 7-15.
64. Wilson, L.A.; Gemin, A.; Espiritu, R.; Singh, G. ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. FASEB J., 2005, 19(14), 2085-2087.
65. Dhakshinamoorthy, S.; Porter, A.G. Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. J. Biol. Chem., 2004, 279(19), 20096-20107.
66. Park, E.Y.; Kim, S.G. NO signaling in ARE-mediated gene expression. Methods Enzymol., 2005, 396, 341-349.
67. Dhakshinamoorthy, S.; Jaiswal, A.K. Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene, 2001, 20(29), 3906-3917.
68. Eggler, A.L.; Liu, G.; Pezzuto, J.M.; van Breemen, R.B.; Mesecar, A.D. Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2. Proc. Natl. Acad. Sci. U S A., 2005, 102(29), 10070-10075.
69. Velichkova, M.; Hasson, T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol. Cell Biol., 2005, 25(11), 4501-4513.
70. Rushmore, T.H.; Morton, M.R.; Pickett, C.B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem., 1991, 266(18), 11632-11639.
71. Rushmore, T.H.; King, R.G.; Paulson, K.E.; Pickett, C.B. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc. Natl. Acad. Sci. U S A., 1990, 87(10), 3826-3830.
72. Dinkova-Kostova, A.T.; Holtzclaw, W.D.; Kensler, T.W. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol., 2005, 18(12), 1779-1791.
73. Kobayashi, M.; Yamamoto, M. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul., 2006, 46, 113-140.
74. Rojo, A.I.; Sagarra, M.R.; Cuadrado, A. GSK-3beta downregulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J. Neurochem., 2008, 105(1), 192-202.
75. Tong, K.I.; Katoh, Y.; Kusunoki, H.; Itoh, K.; Tanaka, T.; Yamamoto, M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell Biol., 2006, 26(8), 2887-2900.
76. Lee, J.M.; Li, J.; Johnson, D.A.; Stein, T.D.; Kraft, A.D.; Calkins, M.J.; Jakel, R.J.; Johnson, J.A. Nrf2, a multi-organ protector? FASEB J., 2005, 19(9), 1061-1066.
77. Jaiswal, A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med., 2004, 36(10), 1199-1207.
78. Giudice, A.; Montella, M. Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention. Bioessays, 2006, 28(2), 169-181.
79. Zhang, Y.; Gordon, G.B. A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway. Mol. Cancer Ther., 2004, 3(7), 885-893.
80. Bilban, M.; Haschemi, A.; Wegiel, B.; Chin, B.Y.; Wagner, O.; Otterbein, L.E. Heme oxygenase and carbon monoxide initiate homeostatic signaling. J. Mol. Med(Berl)., 2008, 86(3), 267-279.
81. Jenner, P.; Olanow, C.W. The pathogenesis of cell death in Parkinson's disease. Neurology, 2006, 66(10 Suppl 4), S24-36.
82. Cuadrado, A.; Rojo, A.I. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr. Pharm. Des., 2008, 14(5), 429-442.
83. Schipper, H.M.; Liberman, A.; Stopa, E.G. Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp. Neurol., 1998, 150(1), 60-68.
84. Chen, P.C.; Vargas, M.R.; Pani, A.K.; Smeyne, R.J.; Johnson, D.A.; Kan, Y.W.; Johnson, J.A. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc. Natl. Acad. Sci. U S A., 2009, 106(8), 2933-2938.
85. Hung, S.Y.; Liou, H.C.; Kang, K.H.; Wu, R.M.; Wen, C.C.; Fu, W.M. Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. Mol. Pharmacol., 2008, 74(6), 1564-1575.
86. Lastres-Becker, I.; Ulusoy, A.; Innamorato, N.G.; Sahin, G.; Rabano, A.; Kirik, D.; Cuadrado, A. alpha-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Hum. Mol. Genet., 2012.
87. Innamorato, N.G.; Jazwa, A.; Rojo, A.I.; Garcia, C.; Fernandez-Ruiz, J.; Grochot-Przeczek, A.; Stachurska, A.; Jozkowicz, A.; Dulak, J.; Cuadrado, A. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One, 2010, 5(7), e11838.
88. Joseph, P.; Long, D.J., 2nd; Klein-Szanto, A.J.; Jaiswal, A.K. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem. Pharmacol., 2000, 60(2), 207-214.
89. Cavelier, G.; Amzel, L.M. Mechanism of NAD(P)H:quinone reductase: Ab initio studies of reduced flavin. Proteins, 2001, 43(4), 420-432.
90. van Muiswinkel, F.L.; de Vos, R.A.; Bol, J.G.; Andringa, G.; Jansen Steur, E.N.; Ross, D.; Siegel, D.; Drukarch, B. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol. Aging, 2004, 25(9), 1253-1262.
91. Han, J.M.; Lee, Y.J.; Lee, S.Y.; Kim, E.M.; Moon, Y.; Kim, H.W.; Hwang, O. Protective effect of sulforaphane against dopaminergic cell death. J. Pharmacol. Exp. Ther., 2007, 321(1), 249-256.
92. Andrea C. Kil, B.D.; Allert J. Jonker, Henk J. Groenewegen and Pieter Voorn. Upregulation of NAD(P)H:Quinone Oxidoreductase (NQO1) in Glial Cells of 6-Hydroxydopamine-Lesioned Substantia Nigra in the Rat. Adv. in Behav. Biol., 2009, 58(4), 411-429.
93. Dickinson, D.A.; Forman, H.J. Cellular glutathione and thiols metabolism. Biochem. Pharmacol., 2002, 64(5-6), 1019-1026.
94. Zeevalk, G.D.; Razmpour, R.; Bernard, L.P. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed. Pharmacother., 2008, 62(4), 236-249.
95. Huang, C.S.; Anderson, M.E.; Meister, A. Amino acid sequence and function of the light subunit of rat kidney gammaglutamylcysteine synthetase. J. Biol. Chem., 1993, 268(27), 20578-20583.
96. Huang, C.S.; Chang, L.S.; Anderson, M.E.; Meister, A. Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. J. Biol. Chem., 1993, 268(26), 19675-19680.
97. Lu, S.C.; Huang, Z.Z.; Yang, H.; Tsukamoto, H. Effect of thioacetamide on the hepatic expression of gammaglutamylcysteine synthetase subunits in the Rat. Toxicol. Appl. Pharmacol., 1999, 159(3), 161-168.
98. Sian, J.; Dexter, D.T.; Lees, A.J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol., 1994, 36(3), 348-355.
99. Sofic, E.; Lange, K.W.; Jellinger, K.; Riederer, P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 1992, 142(2), 128-130.
100. Griffith, O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med., 1999, 27(9-10), 922-935.
101. Rangasamy, T.; Cho, C.Y.; Thimmulappa, R.K.; Zhen, L.; Srisuma, S.S.; Kensler, T.W.; Yamamoto, M.; Petrache, I.; Tuder, R.M.; Biswal, S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest., 2004, 114(9), 1248-1259.
102. Thimmulappa, R.K.; Lee, H.; Rangasamy, T.; Reddy, S.P.; Yamamoto, M.; Kensler, T.W.; Biswal, S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Invest., 2006, 116(4), 984-995.
103. Goven, D.; Boutten, A.; Lecon-Malas, V.; Marchal-Somme, J.; Amara, N.; Crestani, B.; Fournier, M.; Leseche, G.; Soler, P.; Boczkowski, J.; Bonay, M. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax, 2008, 63(10), 916-924.
104. Erickson, A.M.; Nevarea, Z.; Gipp, J.J.; Mulcahy, R.T. Identification of a variant antioxidant response element in the promoter of the human glutamate-cysteine ligase modifier subunit gene. Revision of the ARE consensus sequence. J. Biol. Chem., 2002, 277(34), 30730-30737.
105. Sasaki, H.; Sato, H.; Kuriyama-Matsumura, K.; Sato, K.; Maebara, K.; Wang, H.; Tamba, M.; Itoh, K.; Yamamoto, M.; Bannai, S. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem., 2002, 277(47), 44765-44771.
106. Singh, A.; Rangasamy, T.; Thimmulappa, R.K.; Lee, H.; Osburn, W.O.; Brigelius-Flohe, R.; Kensler, T.W.; Yamamoto, M.; Biswal, S. Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. Am. J. Respir. Cell Mol. Biol., 2006, 35(6), 639-650.
107. Harvey, C.J.; Thimmulappa, R.K.; Singh, A.; Blake, D.J.; Ling, G.; Wakabayashi, N.; Fujii, J.; Myers, A.; Biswal, S. Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radic. Biol. Med., 2009, 46(4), 443-453.
108. Suh, J.H.; Shenvi, S.V.; Dixon, B.M.; Liu, H.; Jaiswal, A.K.; Liu, R.M.; Hagen, T.M. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl. Acad. Sci. U S A., 2004, 101(10), 3381-3386.
109. Suh, J.H.; Wang, H.; Liu, R.M.; Liu, J.; Hagen, T.M. (R)-alphalipoic acid reverses the age-related loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch. Biochem. Biophys., 2004, 423(1), 126-135.
110. Zhu, Y.; Carvey, P.M.; Ling, Z. Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res., 2006, 1090(1), 35-44.
111. Clements, C.M.; McNally, R.S.; Conti, B.J.; Mak, T.W.; Ting, J.P. DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl. Acad. Sci. U S A., 2006, 103(41), 15091-15096.
112. Yang, W.; Chen, L.; Ding, Y.; Zhuang, X.; Kang, U.J. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum Mol Genet. 2007, 16(23), 2900-2910.
113. Im, J.Y.; Lee, K.W.; Woo, J.M.; Junn, E., Mouradian, M.M. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum. Mol. Genet., 2012.
114. Ramsey, C.P.; Glass, C.A.; Montgomery, M.B.; Lindl, K.A.; Ritson, G.P.; Chia, L.A.; Hamilton, R.L.; Chu, C.T.; Jordan-Sciutto, K.L. Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol., 2007, 66(1), 75-85.
115. von Otter, M.; Landgren, S.; Nilsson, S.; Celojevic, D.; Bergstrom, P.; Hakansson, A.; Nissbrandt, H.; Drozdzik, M.; Bialecka, M.; Kurzawski, M.; Blennow, K.; Nilsson, M.; Hammarsten, O.; Zetterberg, H. Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med. Genet., 2010, 11, 36.
116. Siebert, A.; Desai, V.; Chandrasekaran, K.; Fiskum, G.; Jafri, M.S. Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. J. Neurosci. Res., 2009, 87(7), 1659-1669.
117. Cook, A.L.; Vitale, A.M.; Ravishankar, S.; Matigian, N.; Sutherland, G.T.; Shan, J.; Sutharsan, R.; Perry, C.; Silburn, P.A.; Mellick, G.D.; Whitelaw, M.L.; Wells, C.A.; Mackay-Sim, A.; Wood, S.A. NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease. PLoS One, 2011, 6(7), e21907.
118. Williamson, T.P.; Johnson, D.A.; Johnson, J.A. Activation of the Nrf2-ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTPmediated neurotoxicity. Neurotoxicology, 2012, 33(3), 272-279.
119. Cao, T.T.; Ma, L.; Kandpal, G.; Warren, L.; Hess, J.F.; Seabrook, G.R. Increased nuclear factor-erythroid 2 p45-related factor 2 activity protects SH-SY5Y cells against oxidative damage. J. Neurochem., 2005, 95(2), 406-417.
120. Wakabayashi, N.; Itoh, K.; Wakabayashi, J.; Motohashi, H.; Noda, S.; Takahashi, S.; Imakado, S.; Kotsuji, T.; Otsuka, F.; Roop, D.R.; Harada, T.; Engel, J.D.; Yamamoto, M. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet., 2003, 35(3), 238-245.
121. Satoh, T.; Harada, N.; Hosoya, T.; Tohyama, K.; Yamamoto, M.; Itoh, K. Keap1/Nrf2 system regulates neuronal survival as revealed through study of keap1 gene-knockout mice. Biochem. Biophys. Res. Commun., 2009, 380(2), 298-302.
122. Barone, M.C.; Sykiotis, G.P.; Bohmann, D. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis. Model Mech., 2011, 4(5), 701-707.
123. Rojo, A.I.; Innamorato, N.G.; Martin-Moreno, A.M.; De Ceballos, M.L.; Yamamoto, M.; Cuadrado, A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia, 2010, 58(5), 588-598.
124. Jazwa, A.; Rojo, A.I.; Innamorato, N.G.; Hesse, M.; Fernandez-Ruiz, J.; Cuadrado, A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox Signal, 2011, 14(12), 2347-2360.
125. Burton, N.C.; Kensler, T.W.; Guilarte, T.R. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology, 2006, 27(6), 1094-1100.
126. Lee, J.M.; Shih, A.Y.; Murphy, T.H.; Johnson, J.A. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J. Biol. Chem., 2003, 278(39), 37948-37956.
127. Niso-Santano, M.; Gonzalez-Polo, R.A.; Bravo-San Pedro, J.M.; Gomez-Sanchez, R.; Lastres-Becker, I.; Ortiz-Ortiz, M.A.; Soler, G.; Moran, J.M.; Cuadrado, A.; Fuentes, J.M. Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquatinduced cell death: modulation by the Nrf2/Trx axis. Free Radic. Biol. Med., 2010, 48(10), 1370-1381.
128. Jakel, R.J.; Townsend, J.A.; Kraft, A.D.; Johnson, J.A. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res., 2007, 1144, 192-201.
129. Innamorato, N.G.; Rojo, A.I.; Garcia-Yague, A.J.; Yamamoto, M.; de Ceballos, M.L.; Cuadrado, A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol., 2008, 181(1), 680-689.
130. Pehar, M.; Vargas, M.R.; Robinson, K.M.; Cassina, P.; Diaz-Amarilla, P.J.; Hagen, T.M.; Radi, R.; Barbeito, L.; Beckman, J.S. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J. Neurosci., 2007, 27(29), 7777-7785.
131. Yamamoto, N.; Sawada, H.; Izumi, Y.; Kume, T.; Katsuki, H.; Shimohama, S.; Akaike, A. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J. Biol. Chem., 2007, 282(7), 4364-4372.
132. Wruck, C.J.; Claussen, M.; Fuhrmann, G.; Romer, L.; Schulz, A.; Pufe, T.; Waetzig, V.; Peipp, M.; Herdegen, T.; Gotz, M.E. Luteolin protects rat PC12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keap1-Nrf2-ARE pathway. J. Neural. Transm. Suppl., 2007, (72), 57-67.
133. Niture, S.K.; Jaiswal, A.K. Nrf2 Protein Up-regulates Antiapoptotic Protein Bcl-2 and Prevents Cellular Apoptosis. J. Biol. Chem., 2012, 287(13), 9873-9886.
134. Hara, H.; Ohta, M.; Adachi, T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J. Neurosci. Res., 2006, 84(4), 860-866.
135. Nakaso, K.; Nakamura, C.; Sato, H.; Imamura, K.; Takeshima, T.; Nakashima, K. Novel cytoprotective mechanism of antiparkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem. Biophys. Res. Commun., 2006, 339(3), 915-922.
136. Xiao, H.; Lv, F.; Xu, W.; Zhang, L.; Jing, P.; Cao, X. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology, 2011, 290(2-3), 286-294.
137. Lim, J.H.; Kim, K.M.; Kim, S.W.; Hwang, O.; Choi, H.J. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol. Res., 2008, 57(5), 325-331.
138. Martin, H.L.; Mounsey, R.B.; Mustafa, S.; Sathe, K.; Teismann, P. Pharmacological manipulation of peroxisome proliferator-activated receptor gamma (PPARgamma) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp. Neurol., 2012, 235(2), 528-538.
139. Trinh, K.; Andrews, L.; Krause, J.; Hanak, T.; Lee, D.; Gelb, M.; Pallanck, L. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. J. Neurosci., 2010, 30(16), 5525-5532.
140. Genc, K.; Egrilmez, M.Y.; Genc, S. Erythropoietin induces nuclear translocation of Nrf2 and heme oxygenase-1 expression in SHSY5Y cells. Cell Biochem. Funct., 2010, 28(3), 197-201.
141. Lee, I.S.; Ryu, D.K.; Lim, J.; Cho, S.; Kang, B.Y.; Choi, H.J. Artesunate activates Nrf2 pathway-driven anti-inflammatory potential through ERK signaling in microglial BV2 cells. Neurosci. Lett., 2012, 509(1), 17-21.
142. Hwang, Y.P.; Jeong, H.G. The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett., 2008, 582(17), 2655-2662.
143. Hwang, Y.P.; Jeong, H.G. Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol. Appl. Pharmacol., 2010, 242(1), 18-28.
144. Yang, L.; Calingasan, N.Y.; Thomas, B.; Chaturvedi, R.K.; Kiaei, M.; Wille, E.J.; Liby, K.T.; Williams, C.; Royce, D.; Risingsong, R.; Musiek, E.S.; Morrow, J.D.; Sporn, M.; Beal, M.F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One, 2009, 4(6), e5757.
145. Quesada, A.; Ogi, J.; Schultz, J.; Handforth, A. C-terminal mechano-growth factor induces heme oxygenase-1-mediated neuroprotection of SH-SY5Y cells via the protein kinase C/Nrf2 pathway. J. Neurosci. Res., 2011, 89(3), 394-405.
146. Lou, H.; Jing, X.; Ren, D.; Wei, X.; Zhang, X. Eriodictyol protects against H(2)O(2)-induced neuron-like PC12 cell death through activation of Nrf2/ARE signaling pathway. Neurochem. Int. 2012, 61(2), 251-257.
147. Kim, S.S.; Lim, J.; Bang, Y.; Gal, J.; Lee, S.U.; Cho, Y.C.; Yoon, G.; Kang, B.Y.; Cheon, S.H.; Choi, H.J. Licochalcone E activates Nrf2/antioxidant response element signaling pathway in both neuronal and microglial cells: therapeutic relevance to neurodegenerative disease. J. Nutr. Biochem. 2012.
148. Huang, J.Y.; Chuang, J.I. Fibroblast growth factor 9 upregulates heme oxygenase-1 and gamma-glutamylcysteine synthetase expression to protect neurons from 1-methyl-4-phenylpyridinium toxicity. Free Radic. Biol. Med., 2010, 49(6), 1099-1108.
149. Hwang, Y.P.; Kim, H.G.; Han, E.H.; Jeong, H.G. Metallothionein-III protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a PI3K and ERK/Nrf2-dependent manner. Toxicol. Appl. Pharmacol., 2008, 231(3), 318-327.
150. Uruno, A.; Motohashi, H. The Keap1-Nrf2 system as an in vivo sensor for electrophiles. Nitric Oxide., 2011, 25(2), 153-160.
151. Prestera, T.; Zhang, Y.; Spencer, S.R.; Wilczak, C.A.; Talalay, P. The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul., 1993, 33, 281-296.
152. Lau, A.; Villeneuve, N.F.; Sun, Z.; Wong, P.K.; Zhang, D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res., 2008, 58(5-6), 262-270.
153. Sykiotis, G.P.; Bohmann, D. Stress-activated cap'n'collar transcription factors in aging and human disease. Sci. Signal., 2010, 3(112), re3.
154. Wilkinson, B.; Micklefield, J. Mining and engineering naturalproduct biosynthetic pathways. Nat. Chem. Biol., 2007, 3(7), 379-386.
155. Tran, T.A.; McCoy, M.K.; Sporn, M.B.; Tansey, M.G. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J. Neuroinflammation, 2008, 5, 14.
156. Yates, M.S.; Tauchi, M.; Katsuoka, F.; Flanders, K.C.; Liby, K.T.; Honda, T.; Gribble, G.W.; Johnson, D.A.; Johnson, J.A.; Burton, N.C.; Guilarte, T.R.; Yamamoto, M.; Sporn, M.B.; Kensler, T.W. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer. Ther., 2007, 6(1), 154-162.
157. Pergola, P.E.; Raskin, P.; Toto, R.D.; Meyer, C.J.; Huff, J.W.; Grossman, E.B.; Krauth, M.; Ruiz, S.; Audhya, P.; Christ-Schmidt, H.; Wittes, J.; Warnock, D.G. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med., 2011, 365(4), 327-336.
158. New Anti-Inflammation Modulator Improves Kidney/Diabetes Functions; for CNS disease too [cited; http://www.natap.org/2009/HIV/062109_062103.htm]. Available from: http://www.natap.org/2009/HIV/062109_03.htm (accessed May 17,2012).
159. Satoh, T.; Kosaka, K.; Itoh, K.; Kobayashi, A.; Yamamoto, M.; Shimojo, Y.; Kitajima, C.; Cui, J.; Kamins, J.; Okamoto, S.; Izumi, M.; Shirasawa, T.; Lipton, S.A. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J. Neurochem., 2008, 104(4), 1116-1131.
160. Satoh, T.; Okamoto, S.I.; Cui, J.; Watanabe, Y.; Furuta, K.; Suzuki, M.; Tohyama, K.; Lipton, S.A. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophillic] phase II inducers. Proc. Natl. Acad. Sci. U S A, 2006, 103(3), 768-773.
161. Kraft, A.D.; Johnson, D.A.; Johnson, J.A. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tertbutylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci., 2004, 24(5), 1101-1112.
162. Sasaki, S.; Tozawa, T.; Van Wagoner, R.M.; Ireland, C.M.; Harper, M.K.; Satoh, T. Strongylophorine-8, a pro-electrophilic compound from the marine sponge Petrosia (Strongylophora) corticata, provides neuroprotection through Nrf2/ARE pathway. Biochem. Biophys. Res. Commun., 2011, 415(1), 6-10.
163. Kensler, T.W.; Curphey, T.J.; Maxiutenko, Y.; Roebuck, B.D. Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins. Drug Metabol. Drug Interact., 2000, 17(1-4), 3-22.
164. Li, X.H.; Li, C.Y.; Lu, J.M.; Tian, R.B.; Wei, J. Allicin ameliorates cognitive deficits ageing-induced learning and memory deficits through enhancing of Nrf2 antioxidant signaling pathways. Neurosci. Lett., 2012, 514(1), 46-50.
165. Chen, C.; Pung, D.; Leong, V.; Hebbar, V.; Shen, G.; Nair, S.; Li, W.; Kong, A.N. Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor Nrf2: effect of chemical structure and stress signals. Free Radic. Biol. Med., 2004, 37(10), 1578-1590.
166. Kim, H.S.; Skurk, C.; Thomas, S.R.; Bialik, A.; Suhara, T.; Kureishi, Y.; Birnbaum, M.; Keaney, J.F.; Jr., Walsh, K. Regulation of angiogenesis by glycogen synthase kinase-3beta. J. Biol. Chem., 2002, 277(44), 41888-41896.
167. Salazar, M.; Rojo, A.I.; Velasco, D.; de Sagarra, R.M.; Cuadrado, A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem., 2006, 281(21), 14841-14851.
168. Kozikowski, A.P.; Gaisina, I.N.; Petukhov, P.A.; Sridhar, J.; King, L.T.; Blond, S.Y.; Duka, T.; Rusnak, M.; Sidhu, A. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. Chem. Med. Chem., 2006, 1(2), 256-266.
169. Chen, G.; Bower, K.A.; Ma, C.; Fang, S.; Thiele, C.J.; Luo, J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB. J., 2004, 18(10), 1162-1164.
170. Nagao, M.; Hayashi, H. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci. Lett., 2009, 449(2), 103-107.
171. Duka, T.; Duka, V.; Joyce, J.N.; Sidhu, A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB. J., 2009, 23(9), 2820-2830.
172. Ikeyama, S.; Kokkonen, G.; Shack, S.; Wang, X.T.; Holbrook, N.J. Loss in oxidative stress tolerance with aging linked to reduced extracellular signal-regulated kinase and Akt kinase activities. FASEB. J., 2002, 16(1), 114-116.
173. Jain, A.K.; Jaiswal, A.K. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J. Biol. Chem., 2006, 281(17), 12132-12142.
174. Jain, A.K.; Jaiswal, A.K. GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J. Biol. Chem., 2007, 282(22), 16502-16510.
175. Nakamura, T.; Yamashita, H.; Takahashi, T.; Nakamura, S. Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun., 2001, 280(4), 1085-1092.
176. Dhakshinamoorthy, S.; Jain, A.K.; Bloom, D.A.; Jaiswal, A.K. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J. Biol. Chem., 2005, 280(17), 16891-16900.